2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Myasthenia Gravis
5
Neoplasms, Plasma Cell
3
Neoplasms
3
Multiple Myeloma
2
Lymphoma
2
Leukemia
2
Infections
2
Hematologic Neoplasms
2
Urologic Neoplasms
1
Neuromyelitis Optica
1
Neuroblastoma
1
Myelitis, Transverse
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Limbic Encephalitis
1
Immunoglobulin Light-chain Amyloidosis
1
Epilepsy
1
Epilepsies, Partial
1
Drug Resistant Epilepsy
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Autoimmune Diseases of the Nervous System
1
Autoimmune Diseases
1
Interventions
Carboplatin
784
Pemetrexed
607
Cisplatin
545
Paclitaxel
491
pembrolizumab
464
Docetaxel
440
Gemcitabine
328
Erlotinib Hydrochloride
307
Radiotherapy
258
Nivolumab
244
Bevacizumab
233
osimertinib
178
Drug Therapy
164
durvalumab
157
atezolizumab
135
Gefitinib
134
Radiosurgery
133
Vinorelbine
111
Cetuximab
97
130-nm albumin-bound paclitaxel
94
Ipilimumab
86
Magnetic Resonance Spectroscopy
84
Taxes
79
Surgical Procedures, Operative
74
Afatinib
68
Albumin-Bound Paclitaxel
66
Specimen Handling
61
Etoposide
61
Cyclophosphamide
60
tislelizumab
59
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
Immunoglobulins, Intravenous
×
Clear all
NCT06064279
2024-09-19
HAITEN-ICI
VA Office of Research and Development
Phase 1/2
Withdrawn